DHR Add to watchlist $182.67 +2.04 (+1.13%) Last updated: May 31, 2026 03:04
52-Week Range
$182.67
$160.93 $182.67 $242.80

Fundamentals Overview

Danaher Corporation is in the middle of its 52-week range with premium valuation, trading relatively flat today.

Valuation premium

P/E 35.2 P/B 2.44 P/S 5.22

Intrinsic value (DCF)

+24.1% upside vs price

Profitability

Net margin 14.9%

Risk (Beta)

0.84 — in line vol

Earnings & growth

EPS $5.19 Rev -13% Profit -14% vs prior qtr

BullzEye Analysis

Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Hold — 54% confidence Risk: Moderate Volatility — Beta 0.84. Diversify and only invest what you can afford to lose.

Supporting (Buy):

DCF +24.1% upside vs price · Analyst grade: B

Pressures (Sell):

Sentiment weakening (2 downgrades) · 3M vs S&P 500: -22% · 3M vs Healthcare sector: -7.5%

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$129.29B
P/E (TTM)
35.22
EPS (TTM)
$5.19
Dividend Yield
0.74%
52-Week Range
$160.93 - $242.80
Volume vs Avg
N/A
Beta
0.84

About

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy. This segment also offers bioprocess...
Sector: Healthcare
Headquarters: US
Employees: 61,000
IPO Date: Dec 1978
Beta: 0.84 (Less volatile than market)

Ratings & Grades at a Glance

Overall rating: B. Recent institutional grades: majority downgrades. Current institutional positions: Buy: 10, Equal Weight: 4, Neutral: 2, Outperform: 8, Overweight: 5, Sector Outperform: 1.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $226.75; current price is $182.67. That’s a +24.1% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric Value
Valuation
P/E (TTM) 35.22
DCF value (model) $226.75 (24.1% upside)
PEG (TTM) N/A
P/B (TTM) 2.44
P/S (TTM) 5.22
P/FCF (TTM) 24.44
Liquidity & enterprise
Current Ratio (TTM) 1.87
Quick Ratio (TTM) 1.52
Cash Ratio (TTM) 0.76
Profitability
ROE (TTM) N/A
ROA (TTM) N/A
Revenue growth (YoY) N/A
Net margin (TTM) 14.89%
Gross margin (TTM) 60.68%
Operating margin (TTM) 20.95%
Debt to equity (TTM) N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for DHR.

Analyst Sentiment at a Glance

B Sentiment Weakening
Buy 10Equal Weight 4Neutral 2Outperform 8Overweight 5Sector Outperform 1
1 upgrade, 2 downgrades
Price Target Consensus
Current $182.67
Median $247.00
Consensus $242.30
Low consensus $200.00
High consensus $270.00

Stock Grades (Institutions)

Institution Action Previous Grade New Grade Date
Citigroup downgrade Buy Neutral 2026-05-27
Morgan Stanley maintain Overweight Overweight 2026-04-23
Baird maintain Outperform Outperform 2026-04-22
Guggenheim maintain Buy Buy 2026-04-22
UBS maintain Buy Buy 2026-04-22
Wells Fargo maintain Equal Weight Equal Weight 2026-04-22
Baird maintain Outperform Outperform 2026-04-17
Barclays maintain Overweight Overweight 2026-04-14
Goldman Sachs maintain Buy Buy 2026-04-13
Evercore ISI Group maintain Outperform Outperform 2026-04-06
Jefferies maintain Buy Buy 2026-01-29
JP Morgan maintain Overweight Overweight 2026-01-29
TD Cowen maintain Buy Buy 2026-01-07
Guggenheim maintain Buy Buy 2026-01-05
Wells Fargo maintain Equal Weight Equal Weight 2025-12-15
Wells Fargo maintain Equal Weight Equal Weight 2025-10-23
Barclays maintain Overweight Overweight 2025-10-22
TD Cowen maintain Buy Buy 2025-10-22
Rothschild & Co downgrade Buy Neutral 2025-10-08
Evercore ISI Group maintain Outperform Outperform 2025-10-07
B of A Securities maintain Buy Buy 2025-09-22
Guggenheim maintain Buy Buy 2025-07-23
UBS maintain Buy Buy 2025-07-23
Baird maintain Outperform Outperform 2025-07-23
Wells Fargo maintain Equal Weight Equal Weight 2025-07-23
Baird maintain Outperform Outperform 2025-07-18
Scotiabank upgrade Sector Perform Sector Outperform 2025-07-11
Evercore ISI Group maintain Outperform Outperform 2025-07-08
Barclays maintain Overweight Overweight 2025-06-24
RBC Capital maintain Outperform Outperform 2025-04-23